IMTV014 / Immgenuity - LARVOL DELTA

Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV (GlobeNewswire) - "Immune Therapeutics...announces the signing of a research collaboration agreement with Immgenuity, Inc. The joint research will focus on using Immgenuity’s IMTV014 and Biostax’s Lodonal™ and JKB-122 both independently and together to determine if the immune modulatory effects of Biostax’s drug therapies combined with Immgenuity’s IMTV014 can achieve remission with HIV patients. Under the terms of the agreement, Immgenuity and Biostax will collaborate to advance the development of novel immunotherapies for the treatment of HIV and other diseases."

Licensing / partnership • Human Immunodeficiency Virus